Management team

Richard Ding, CEO
Richard Ding has over 17 years of management experience in the pharmaceutical and diagnostics industry. As a member of the team at Myriad Genetics that cloned BRCA1 gene, Richard Ding made a significant contribution to the development of one of the first molecular genetic tests. Prior to becoming CEO of bioTheranostics, Richard Ding had taken various cross-functional positions at Eli Lilly and Company. In addition to his current role at bioTheranostics, Richard serves on the Executive Committee at bioMérieux as head of Strategy and Business Development. Richard holds an MBA from the University of Utah and received his undergraduate education and scientific training at Fudan University, China.

Mark Erlander, Ph.D., Chief Scientific Officer
Dr. Mark Erlander has more than 18 years of experience directing and leading research and development for gene discovery as it relates to drug discovery and molecular diagnostics. Prior to joining bioTheranostics, Dr. Erlander was a group leader and subsequently a research fellow at the R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson). He was also an assistant member and postdoctoral fellow at The Scripps Research Institute in the Department of Molecular Biology. Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; an MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles. He is an accomplished researcher with 32 issued U.S. patents and 34 U.S. patent applications, and is author of  55 scientific papers.

Board of directors

Stéphane Bancel, Chairman, bioTheranostics Inc. | Chief Executive Officer, bioMérieux
From 2000 to 2006, Stéphane Bancel worked in the United States, Great Britain and Belgium for Eli Lilly laboratories, where he successively held the positions of Managing Director, Executive Director for Global Manufacturing Strategy, Global Supply Chain & U.S. Distribution, and Manager of Supply Chain. From 1995 to 1998, Bancel worked at bioMérieux in Japan where he was in charge of the industrial microbiology business for the Asia-Pacific region. He is a graduate of the Ecole Centrale Paris Engineering School, and holds an MS in Biochemical Engineering from the University of Minnesota, as well as an MBA from Harvard Business School.

Lale White, Executive Chairman and CEO
Lale White is founder and CEO of XIFIN, Inc. XIFIN is the innovator and provider of a new accounts receivable and financial management application for the healthcare industry.  Ms White is a nationally recognized expert in the field of medical financial management and regulatory compliance.  She lectures and consults extensively on these topics to major laboratories and laboratory associations throughout the U.S.  She has over 20 years of successful executive leadership in financial management, information systems development and medical billing with several of the largest independent clinical reference laboratories where she held senior management positions.  Prior to founding XIFIN, Ms. White was Vice President of Finance at Laboratory Corporation of America.  She was also a principal contributor in working with HCFA and the U.S. Office Of The Inspector General to develop the current “OIG Model Compliance Program.” Lale holds an MBA degree in Finance from Florida International University.

Christian Bréchot, Ph.D., VP Medical and Scientific Affairs, Mérieux Alliance
From 2001 to 2007, Dr. Christian Bréchot was the General Director of INSERM, the French National Agency for biomedical research. Prior to that, he headed the Clinical Department of Liver Diseases at the Necker-Enfants Malades Hospital. Dr. Bréchot is the author of more than 350 articles published in medical and scientific journals. His research activities have led him to obtain 13 patents, which have contributed to the creation of two biotech companies. Dr. Bréchot began his studies in molecular biology, virology, and cellular biology at the laboratory of Pierre Tiollais at the Pasteur Institute, and at the Necker Faculty of Medicine in 1981. He obtained his Ph.D. in Biochemistry from the University of Paris VII in 1985.